Prelude Therapeutics Inc (PRLD) stock
PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 8/3066% above fair value
$3.52−0.26 (-6.88%)
Close on Nov 12, 2026Market cap $280.91MP/E –Yield –
Prelude Therapeutics cash
Cash and short-term investments held at the end of each period.
Prelude Therapeutics's cash was $151.76M at Jun 30, 2026. For fiscal 2025 it was $103.21M, down 22.8% from the year before. The highest annual figure on record is $291.23M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.21M | -22.8% |
| FY2024 | Dec 31, 2024 | $133.61M | -42.6% |
| FY2023 | Dec 31, 2023 | $232.94M | +15.5% |
| FY2022 | Dec 31, 2022 | $201.73M | -30.7% |
| FY2021 | Dec 31, 2021 | $291.23M | +33.4% |
| FY2020 | Dec 31, 2020 | $218.31M | +1056.4% |
| FY2019 | Dec 31, 2019 | $18.88M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $151.76M | +107.3% |
| Q1 FY2026 | Mar 31, 2026 | $81.55M | -17.7% |
| Q4 FY2025 | Dec 31, 2025 | $103.21M | -22.8% |
| Q3 FY2025 | Sep 30, 2025 | $54.96M | -64.2% |
| Q2 FY2025 | Jun 30, 2025 | $73.22M | -59.3% |
| Q1 FY2025 | Mar 31, 2025 | $99.07M | -50.9% |
| Q4 FY2024 | Dec 31, 2024 | $133.61M | -42.6% |
| Q3 FY2024 | Sep 30, 2024 | $153.63M | -33.4% |
| Q2 FY2024 | Jun 30, 2024 | $179.84M | -29.5% |
| Q1 FY2024 | Mar 31, 2024 | $201.92M | +17.2% |
| Q4 FY2023 | Dec 31, 2023 | $232.94M | +15.5% |
| Q3 FY2023 | Sep 30, 2023 | $230.51M | +2.9% |
| Q2 FY2023 | Jun 30, 2023 | $254.99M | +3.5% |
| Q1 FY2023 | Mar 31, 2023 | $172.26M | -35.3% |
| Q4 FY2022 | Dec 31, 2022 | $201.73M | -30.7% |
| Q3 FY2022 | Sep 30, 2022 | $224.04M | -30.2% |
| Q2 FY2022 | Jun 30, 2022 | $246.31M | -28.2% |
| Q1 FY2022 | Mar 31, 2022 | $266.19M | -26.7% |
| Q4 FY2021 | Dec 31, 2021 | $291.23M | +33.4% |
| Q3 FY2021 | Sep 30, 2021 | $320.87M | +36.7% |
| Q2 FY2021 | Jun 30, 2021 | $343.12M | +1717.5% |
| Q1 FY2021 | Mar 31, 2021 | $362.99M | – |
| Q4 FY2020 | Dec 31, 2020 | $218.31M | – |
| Q3 FY2020 | Sep 30, 2020 | $234.79M | – |
| Q4 FY2019 | Dec 31, 2019 | $18.88M | – |
See a number that looks wrong?